Serentis

About:

Serentis develops medical products and drugs.

Website: http://serentis-pharma.com/

Top Investors: Novo Holdings, MVM Life Science Partners, Apposite Capital, East Hill Advisors

Description:

Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.